Patient safety in distal femoral resection knee arthroplasty for non-tumor indications: a single-center consecutive cohort study of 45 patients.


Journal

BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565

Informations de publication

Date de publication:
03 Mar 2022
Historique:
received: 06 10 2021
accepted: 24 01 2022
entrez: 4 3 2022
pubmed: 5 3 2022
medline: 8 3 2022
Statut: epublish

Résumé

Distal femoral resection knee arthroplasty may be a viable option for several indications other than bone tumors. Resection knee arthroplasty appears to be becoming more common, but patients requiring this type of surgery are often elderly and with high comorbidity. The aim of this study was to report in-hospital complications, readmissions, reoperations, and mortality after distal femoral resection knee arthroplasty for non-tumor indications. We retrospectively identified a consecutive cohort of 45 knees (45 patients) treated with distal femoral resection knee arthroplasty in a single institution between 2012 and 2021. Indications for surgery were failure of osteosynthesis (8), primary fracture treatment (2), periprosthetic fracture (22), and revision arthroplasty with severe bone loss (13). A major reoperation was defined as a major component exchange procedure or amputation. Mean follow-up was 3.9 years. The mean age was 71.3 years (SD 12.3), and 64.4% were female; 8.9% were ASA I, 40% ASA II, and 51% ASA III. Median length of stay was 7 days (range 3-19) with no major in-hospital complications, but 55.6% (n = 25) required blood transfusion. The 90-day readmission rate was 17.8% (n = 8), of which 50% was prosthesis-related. Four patients (8.9%) underwent major reoperation due to infection (n = 2), mechanical failure (n = 1), or periprosthetic fracture (n = 1). The mortality rate was 0% ≤ 90 days and 2.2% ≤1 year. Distal femoral resection knee arthroplasty in this fragile patient population appears to be a viable and safe option considering that it is a limp salvage procedure most cases.

Sections du résumé

BACKGROUND BACKGROUND
Distal femoral resection knee arthroplasty may be a viable option for several indications other than bone tumors. Resection knee arthroplasty appears to be becoming more common, but patients requiring this type of surgery are often elderly and with high comorbidity. The aim of this study was to report in-hospital complications, readmissions, reoperations, and mortality after distal femoral resection knee arthroplasty for non-tumor indications.
METHODS METHODS
We retrospectively identified a consecutive cohort of 45 knees (45 patients) treated with distal femoral resection knee arthroplasty in a single institution between 2012 and 2021. Indications for surgery were failure of osteosynthesis (8), primary fracture treatment (2), periprosthetic fracture (22), and revision arthroplasty with severe bone loss (13). A major reoperation was defined as a major component exchange procedure or amputation. Mean follow-up was 3.9 years.
RESULTS RESULTS
The mean age was 71.3 years (SD 12.3), and 64.4% were female; 8.9% were ASA I, 40% ASA II, and 51% ASA III. Median length of stay was 7 days (range 3-19) with no major in-hospital complications, but 55.6% (n = 25) required blood transfusion. The 90-day readmission rate was 17.8% (n = 8), of which 50% was prosthesis-related. Four patients (8.9%) underwent major reoperation due to infection (n = 2), mechanical failure (n = 1), or periprosthetic fracture (n = 1). The mortality rate was 0% ≤ 90 days and 2.2% ≤1 year.
CONCLUSIONS CONCLUSIONS
Distal femoral resection knee arthroplasty in this fragile patient population appears to be a viable and safe option considering that it is a limp salvage procedure most cases.

Identifiants

pubmed: 35241040
doi: 10.1186/s12891-022-05100-7
pii: 10.1186/s12891-022-05100-7
pmc: PMC8892708
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199

Informations de copyright

© 2022. The Author(s).

Références

J Arthroplasty. 2021 Jul;36(7S):S351-S357
pubmed: 33487512
Arthroplast Today. 2018 Dec 05;5(1):26-31
pubmed: 31020017
Bone Joint J. 2014 Nov;96-B(11):1464-71
pubmed: 25371458
Hip Pelvis. 2020 Mar;32(1):11-16
pubmed: 32158724
J Arthroplasty. 2017 Jan;32(1):202-206
pubmed: 27449717
Int Orthop. 2018 Jan;42(1):191-196
pubmed: 29116356
J Orthop. 2017 Jan 10;14(1):216-222
pubmed: 28115800
Clin Orthop Relat Res. 2011 Apr;469(4):1188-96
pubmed: 20830542
Knee Surg Sports Traumatol Arthrosc. 2021 Oct;29(10):3287-3298
pubmed: 32671435
J Orthop Trauma. 2016 Sep;30(9):503-9
pubmed: 27078131
BMC Musculoskelet Disord. 2017 Apr 4;18(1):144
pubmed: 28376876
Bone Joint J. 2014 Dec;96-B(12):1649-56
pubmed: 25452368
Int Orthop. 2020 Apr;44(4):677-684
pubmed: 31392494
Knee. 2019 Oct;26(5):1080-1087
pubmed: 31420209
J Arthroplasty. 2020 May;35(5):1402-1406
pubmed: 31924488
Injury. 2018 Feb;49(2):392-397
pubmed: 29208310

Auteurs

Yasemin Corap (Y)

Orthopaedic research unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark. Yasemin.corap3@rsyd.dk.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Yasemin.corap3@rsyd.dk.

Michael Brix (M)

Orthopaedic research unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Claus Emmeluth (C)

Orthopaedic research unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Martin Lindberg-Larsen (M)

Orthopaedic research unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH